Flywheel, a research data platform designed for the academic, clinical and life science communities, has announced its launch of Flywheel for Life Sciences. Flywheel for Life Sciences is an enterprise-scale research data management solution helping organizations realize their digital transformation strategy and improve R&D efficiency.
A digital transformation is underway in the life sciences and organizations are motivated to reduce R&D costs, improve operational efficiencies and shorten drug development timelines. To be successful, these organizations need to cost-effectively leverage high-quality data for the exploration of new solutions and reuse data collaboratively within data science & research teams. However, traditional R&D infrastructures are insufficient for large-scale data collection, complex data validation, automated quality controls, and scaling processing (and AI) pipelines.
Flywheel offers a scalable research-first platform that can capture imaging and related data from multiple siloed sources, including CROs and historical clinical trials. Flywheel integrates with existing data pipelines and software tools to ingest multi-modal data, and then consolidate, curate, validate, and disseminate that data to analytics and machine learning platforms. With the provenance to support regulatory approvals and scientific reproducibility, Flywheel supports secure collaboration to solve problems with multi-disciplinary teams internal and external to organizations.
Now with Flywheel for Life Sciences, the solution incorporates new enterprise scaling features that help support the needs of large, global life sciences organizations and their massive volumes of data from diverse sources all over the world. These features include high speed bulk loading, horizontal and vertical scaling, version control deployments, and the provenance to support audit readiness.
Flywheel leverages the full power of modern cloud computing to deliver the performance and reliability needed in the life sciences. Flywheel offers enterprise deployments on major providers such as Amazon Web Services, Google Cloud, and Microsoft Azure. Flywheel for Life Sciences is delivered as a fully managed service allowing digital, operations, data, and clinical teams to focus on research and results rather than IT.
With expertise in medical imaging and computer science, the Flywheel team partners with life sciences organizations to tailor and deliver a system that meets enterprise requirements and critical schedules.
"We are excited to launch our Life Sciences solution to streamline and leverage imaging data assets and machine learning workflows, helping organizations increase R&D efficiency and accelerate drug discovery," said Travis Richardson, Chief Product Officer of Flywheel.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.